LEVOPRONT

This brand name is authorized in Estonia, Lithuania, Poland, Romania, Singapore, Turkey.

Active ingredients

The drug LEVOPRONT contains one active pharmaceutical ingredient (API):

1	Levodropropizine UNII 3O31P6T4G3 - LEVODROPROPIZINE
	Levodropropizine acts directly on the peripheral respiratory sensory nerves rather than affecting the central nervous system. It suppresses the cough reflex by inhibiting the activation of vagal C-fibers and tracheobronchial receptor excitability. It prevents the release of Substance P and other sensory neuropeptides from nerve endings, reducing nerve sensitivity and calming the cough reflex.
	Read more about Levodropropizine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R05DB27	Levodropropizine	R Respiratory system → R05 Cough and cold preparations → R05D Cough suppressants, excl. combinations with expectorants → R05DB Other cough suppressants
Discover more medicines within R05DB27

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1036921, 1077735
LT	Valstybinė vaistų kontrolės tarnyba	1019653, 1019654
PL	Rejestru Produktów Leczniczych	100105368, 100307304, 100334838, 100390860, 100451169
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W59205002, W59206001, W66910001, W66910002
SG	Health Sciences Authority	10823P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699514010920, 8699514010937, 8699514570059, 8699514570066, 8699514573715